Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis.

Mills E, Wilson K, Clarke M, Foster B, Walker S, Rachlis B, DeGroot N, Montori VM, Gold W, Phillips E, Myers S, Gallicano K.

Eur J Clin Pharmacol. 2005 Mar;61(1):1-7. Epub 2005 Jan 22.

PMID:
15666173
2.

Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers.

Piscitelli SC, Formentini E, Burstein AH, Alfaro R, Jagannatha S, Falloon J.

Pharmacotherapy. 2002 May;22(5):551-6.

PMID:
12013352
3.

Coadministration of milk thistle and indinavir in healthy subjects.

DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, Morse G.

Pharmacotherapy. 2003 Jul;23(7):866-70.

PMID:
12885100
4.

Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.

Slain D, Amsden JR, Khakoo RA, Fisher MA, Lalka D, Hobbs GR.

Pharmacotherapy. 2005 Feb;25(2):165-70.

PMID:
15767232
5.

The effect of azithromycin on the pharmacokinetics of indinavir.

Foulds G, LaBoy-Goral L, Wei GC, Apseloff G.

J Clin Pharmacol. 1999 Aug;39(8):842-6.

PMID:
10434237
6.

Milk thistle for the treatment of liver disease: a systematic review and meta-analysis.

Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA.

Am J Med. 2002 Oct 15;113(6):506-15. Review.

PMID:
12427501
7.

Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients.

Cruciani M, Gatti G, Vaccher E, Di Gennaro G, Cinelli R, Bassetti M, Tirelli U, Bassetti D.

J Antimicrob Chemother. 2005 Apr;55(4):546-9. Epub 2005 Feb 22.

PMID:
15728147
8.

Toxicity. Milk thistle and indinavir.

[No authors listed]

TreatmentUpdate. 2002 Sep-Oct;14(7):4-5. No abstract available.

PMID:
12400499
9.

Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin.

Hamzeh FM, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, Ruan P, Wu H, Lee J, Flexner C; AIDS Clinical Trials Group 365 Study Team..

Clin Pharmacol Ther. 2003 Mar;73(3):159-69.

PMID:
12621381
10.

Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.

Jann MW, Spratlin V, Momary K, Zhang H, Turner D, Penzak SR, Wright A, VanDenBerg C.

Eur J Clin Pharmacol. 2012 May;68(5):715-21. doi: 10.1007/s00228-011-1180-7. Epub 2011 Dec 16.

PMID:
22173281
11.

The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin.

Boruchoff SE, Sturgill MG, Grasing KW, Seibold JR, McCrea J, Winchell GA, Kusma SE, Deutsch PJ.

Clin Pharmacol Ther. 2000 Apr;67(4):351-9.

PMID:
10801243
12.

Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans.

Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, Cheboyina S.

Drug Metab Dispos. 2006 Jan;34(1):69-74. Epub 2005 Oct 12.

13.

Effects of St. John's wort extract on indinavir pharmacokinetics in rats: differentiation of intestinal and hepatic impacts.

Ho YF, Huang DK, Hsueh WC, Lai MY, Yu HY, Tsai TH.

Life Sci. 2009 Aug 12;85(7-8):296-302. doi: 10.1016/j.lfs.2009.06.008. Epub 2009 Jun 24.

PMID:
19559714
14.

Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.

McRae M, Clay PG, Anderson PL, Glaros AG.

Pharmacotherapy. 2009 Aug;29(8):937-42. doi: 10.1592/phco.29.8.937.

PMID:
19637947
15.

Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe.

Robertson SM, Formentini E, Alfaro RM, Falloon J, Penzak SR.

Pharmacotherapy. 2006 Aug;26(8):1051-9.

PMID:
16863481
16.

High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.

Goujard C, Legrand M, Panhard X, Diquet B, Duval X, Peytavin G, Vincent I, Katlama C, Leport C, Bonnet B, Salmon-Céron D, Mentré F, Taburet AM; COPHAR1-ANRS 102 Study Group..

Clin Pharmacokinet. 2005;44(12):1267-78.

PMID:
16372824
17.

Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.

von Hentig N, Müller A, Rottmann C, Lutz T, Klauke S, Kurowski M, Staszewski S, Harder S.

Eur J Med Res. 2006 Jun 30;11(6):236-44.

PMID:
16820336
18.

Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers.

Glesby MJ, Aberg JA, Kendall MA, Fichtenbaum CJ, Hafner R, Hall S, Grosskopf N, Zolopa AR, Gerber JG; Adult AIDS Clinical Trials Group A5159 Protocol Team..

Clin Pharmacol Ther. 2005 Aug;78(2):143-53.

PMID:
16084849
19.

Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens.

Dicenzo R, Luque A, Larppanichpoonphol P, Reichman R.

J Antimicrob Chemother. 2006 Aug;58(2):393-400. Epub 2006 Jun 7.

PMID:
16760191
20.

Supplemental Content

Support Center